Traditional industry partnerships fund specific research projects, however there are emerging models that are defining the way companies interact with academic scientists and public organizations. Public-private partnerships are becoming increasingly important to tackle major disease challenges and help accelerate translation of research to address patient needs. Large biopharma companies are looking outside their walls to expand their internal drug discovery expertise within these public-private partnerships, resulting in new and creative collaborations based on close engagement with partners.
This panel will explore unconventional collaboration approaches between companies and academia focused on accelerating translational drug discovery. Panelists will also explore the lessons learned and challenges encountered from the early days of industry-academic partnerships, along with recent successes and best practices in engaging with industry and public organizations to ensure a successful partnership.
Session ID: 21996